KKR, Ares, Tiger Infrastructure pursue ambulance deals; Faster product debuts pave way for ArchiMed’s $1.1bn take-private of Esperion
ArchiMed announced this week the closing of its $1.1 billion take-private of Esperion Therapeutics, a biopharmaceutical company focused on bringing cardiometabolic and rare/orphan disease therapies to market.
17 July 2026•5 mins read
